Alexander Choi
Internal Medicine · Flushing, NYNPI 1104818640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,560 and has fallen 93.9% since, to $95 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$1K
- AbbVie$863
- Amarin Pharma, Inc.$780
- Lilly USA, LLC$710
- Novo Nordisk$507
- Merck$370
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,983100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 10 | $1,076 |
| AbbVie(2 entities) | 52 | $863 |
| Amarin Pharma, Inc. | 27 | $780 |
| Lilly USA, LLC | 38 | $710 |
| Novo Nordisk | 19 | $507 |
| Merck | 16 | $370 |
| Amgen | 10 | $218 |
| Johnson & Johnson | 4 | $197 |
| Astellas Pharma US Inc | 9 | $189 |
| GSK | 9 | $169 |
| AstraZeneca | 8 | $150 |
| Pfizer | 6 | $135 |
| Microvention, Inc. | 1 | $112 |
| Insmed, Inc. | 2 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Boehringer Ingelheim | 3 | $65 |
| Sanofi Pasteur Inc. | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $31 |
| VBI Vaccine (delaware) Inc. | 1 | $27 |
| Gilead | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Vivus LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$352
- Vascepa$243
- XARELTO$125
- Ozempic$123
- WEB$112
- HydroFrame Coil$112
- HydroSoft 3D Coil$112
- LVIS$112
How this compares
$5,994 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 58 | $35,328 |
| CreonLipase/Protease/Amylase | 31 | $34,518 |
| JardianceEmpagliflozin | 47 | $31,768 |
| VascepaIcosapent Ethyl | 104 | $25,174 |
| MyrbetriqMirabegron | 48 | $22,751 |
| Diclofenac Epolamine | 21 | $14,709 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $10,076 |
| Dexlansoprazole DrDexlansoprazole | 13 | $1,842 |
| Icosapent Ethyl | 16 | $1,726 |
| SynthroidLevothyroxine Sodium | 20 | $1,294 |
| Atorvastatin Calcium | 219 | $878 |
| Losartan Potassium | 131 | $579 |
| Galantamine Hbr | 12 | $552 |
| Amlodipine Besylate | 190 | $551 |
| Celecoxib | 25 | $401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $370 | $45,40470 claims |
| AbbVieCreon, Synthroid | $863 | $35,81151 claims |
| Boehringer IngelheimJardiance | $65 | $31,76847 claims |
| Astellas Pharma US IncMyrbetriq | $189 | $22,75148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Weining LiangFlushing$133K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.